ANTHONY CLARK INTERNATIONAL INSURANCE BROKERS LTD. (TSX Venture Exchange: “ACL”); (Pink Sheets: ACKBF) (the “Corporation”) announces that the Trustee for Brooke Corporation et al (“Brooke”), Chapter 7 bankrupt companies, in In re Brooke Corporation Adversary No. 10-06208, voluntarily dismissed (without prejudice) all pending claims against Addison Low Cost Insurance Brokers Ltd. (“Addison Low Cost”) and Addison York Insurance Brokers Ltd. (“Addison York”), both subsidiaries of Anthony Clark International Insurance Brokers Ltd., from this case.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Except for the historical information contained herein, this press release contains statements that constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that may cause or contribute to such differences include, among other things, the Corporation’s ability to close the proposed transaction. Other risks and uncertainties include changes in business conditions and the economy in general, changes in governmental regulations, unforeseen litigation and other risk factors identified in the Corporation’s public filings under Risk Factors. The Corporation undertakes no obligation to update these forward-looking statements for revisions or changes after the date of this press release.

On behalf of ANTHONY CLARK INTERNATIONAL INSURANCE BROKERS LTD.Tony Consalvo”C.E.O.

To view this press release as a web page, please click on the following link:

http://www.usetdas.com/pr/anthonyclark06132011.htm

Copyright Business Wire 2010

If you liked this article you might like

Has IBM Finally Gotten Cheap?

Novartis Profit Falls 4%, Sales Rise 16%

Novartis Profit Falls 4%, Sales Rise 16%

First Solar, Dynegy: Premarket Trading

First Solar, Dynegy: Premarket Trading

Novartis Buys Rest of Alcon Stake for $12.9B

Novartis Buys Rest of Alcon Stake for $12.9B

10 Top Hedge Fund Buys Show M&A Tilt